FULL LIST: 39 UK hospitals testing five-day breast cancer radiotherapy
AI Executive Briefing
Gemini Flash AI~45s readThirty-nine hospitals in the UK are participating in the FAST-Forward Boost trial to evaluate a shortened five-day radiotherapy regimen for breast cancer. This study seeks to improve patient convenience by reducing the treatment duration from three weeks to five days while maintaining efficacy in preventing cancer recurrence.
Context & Background
- ✦The current standard for breast cancer radiotherapy involves a three-week course, which the new trial aims to significantly condense.
- ✦The research is supported by the UK Department of Health and Social Care, highlighting a national effort to optimize cancer treatment efficiency.
Key Figures & Named Entities
•The Institute of Cancer Research, London, is the lead entity for the trial.•The study has a recruitment target of 4,830 participants by 2028, with a five-year follow-up period for each patient.
Outlook & Next Steps
The trial will continue recruiting participants until 2028, followed by a five-year monitoring period, with final results anticipated in 2033.
Key Takeaways
AI Summary- Thirty-nine hospitals across the UK are conducting the FAST-Forward Boost trial to determine if breast cancer radiotherapy can be safely reduced from three weeks to five days.
- The clinical trial aims to prevent cancer recurrence by combining a shorter radiotherapy course with an additional targeted dose.
- Successful implementation of this treatment protocol could spare patients 10 hospital visits per course.
Key Facts:2028: The trial aims to reach its full recruitment target of 4,830 participants.2033: Final results from the clinical trial are expected to be released.
Editorial Excerpt
Thirty-nine hospitals across the UK are part of a clinical trial testing if breast cancer radiotherapy can be safely shortened from three weeks to five day
Frequently Asked Questions About This Story
What is the primary goal of the FAST-Forward Boost trial?
The trial is testing whether a shorter five-day course of radiotherapy, combined with a targeted boost dose, can effectively prevent breast cancer from returning.
Who is funding and leading this research?
The trial is led by the Institute of Cancer Research, London, and is funded by the National Institute for Health and Care Research.
